Clinical Programs

Critical limb ischemia, the most severe form of peripheral vascular disease, leads to over 160,000 major limb amputations per year. Therapeutic options are limited and largely ineffective for the most severe patients. Aastrom is developing Vascular Repair Cells (VRCs), based on TRC technology, with the goal of repairing and regenerating the ischemic tissues of these patients by improving the blood flow in the affected areas.